Diabetic ketoacidosis led to fatal demise, preterm birth, and neonatal intensive care unit admissions.
Implementation of clinical practice guidelines can reduce the length of hospitalizations among children experiencing diabetic ketoacidosis.
For patients with new-onset diabetic ketoacidosis and severe hyperglycemia, metformin and sitagliptin treatment after normoglycemia remission correlate with increased relapse-free survival and prolonged remission.
Compared with standard protocol, patients achieved faster resolution of acidosis and hyperglycemia.
Expert panel recommends continued use of SGLT2 inhibitors, as risk for DKA is low.
Jennifer N. Clements, PharmD, BPCS, CDE, BCACP, reviews some details of the reports of ketocacidosis with the use of SGLT2 inhibitors.
The FDA has issued a warning about the risk for ketoacidosis with the use of SGLT2 inhibitors, which are indicated for the treatment of type 2 diabetes.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
- Sleep Quality, Duration Affect Risk for Falls and Fractures in Older Women
- Physician Burnout Linked to Stress in Using Health Information Technology
- Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
- Urinary Incontinence Drug May Reduce Frequency of Hot Flashes